1. Home
  2. VLY vs INAB Comparison

VLY vs INAB Comparison

Compare VLY & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VLY
  • INAB
  • Stock Information
  • Founded
  • VLY 1927
  • INAB 2016
  • Country
  • VLY United States
  • INAB United States
  • Employees
  • VLY N/A
  • INAB N/A
  • Industry
  • VLY Major Banks
  • INAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • VLY Finance
  • INAB Health Care
  • Exchange
  • VLY Nasdaq
  • INAB Nasdaq
  • Market Cap
  • VLY 5.1B
  • INAB 24.0M
  • IPO Year
  • VLY N/A
  • INAB 2021
  • Fundamental
  • Price
  • VLY $9.16
  • INAB $0.25
  • Analyst Decision
  • VLY Hold
  • INAB Strong Buy
  • Analyst Count
  • VLY 10
  • INAB 3
  • Target Price
  • VLY $9.60
  • INAB $7.75
  • AVG Volume (30 Days)
  • VLY 6.2M
  • INAB 748.9K
  • Earning Date
  • VLY 01-23-2025
  • INAB 11-12-2024
  • Dividend Yield
  • VLY 4.80%
  • INAB N/A
  • EPS Growth
  • VLY N/A
  • INAB N/A
  • EPS
  • VLY 0.62
  • INAB N/A
  • Revenue
  • VLY $1,577,035,000.00
  • INAB N/A
  • Revenue This Year
  • VLY N/A
  • INAB N/A
  • Revenue Next Year
  • VLY $7.09
  • INAB N/A
  • P/E Ratio
  • VLY $14.66
  • INAB N/A
  • Revenue Growth
  • VLY N/A
  • INAB N/A
  • 52 Week Low
  • VLY $6.47
  • INAB $0.22
  • 52 Week High
  • VLY $11.18
  • INAB $1.93
  • Technical
  • Relative Strength Index (RSI)
  • VLY 31.05
  • INAB 39.26
  • Support Level
  • VLY $8.90
  • INAB $0.28
  • Resistance Level
  • VLY $10.27
  • INAB $0.32
  • Average True Range (ATR)
  • VLY 0.33
  • INAB 0.03
  • MACD
  • VLY -0.19
  • INAB -0.01
  • Stochastic Oscillator
  • VLY 14.21
  • INAB 13.73

About VLY Valley National Bancorp

Valley National Bancorp is a bank holding company whose principal wholly-owned subsidiary is Valley National Bank. It provides a full range of commercial, retail, and trust and investment services largely through its offices and ATM network throughout northern and central New Jersey, New York City Long Island, Florida, and Alabama. The segments of the group are commercial lending, consumer lending, investment management, and corporate and other adjustments, of which key interest income is derived from the commercial lending segment. In recent years, the company has focused on acquiring companies that operate outside of traditional banking and has emphasized wealth and capital management.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Share on Social Networks: